NASDAQ: ZYMEZymeworks Inc Stock
$12.35-0.45 (-3.52%)
Updated Mar 26, 2025
ZYME Price
$12.35
Fair Value Price
N/A
Market Cap
$859.27M
52 Week Low
$7.97
52 Week High
$17.70
P/E
-7.62x
P/B
2.54x
P/S
14.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$76.30M
Earnings
-$122.70M
Gross Margin
100%
Operating Margin
-152.82%
Profit Margin
-160.8%
Debt to Equity
0.37
Operating Cash Flow
-$110M
Beta
0.98
Next Earnings
Apr 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ZYME Overview
Zymeworks Incorporated is a clinical-stage biopharmaceutical company that develops and commercializes cancer-treating biotherapeutics. The company's lead candidates include zanidatamab, a bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has partnerships with Merck, Eli Lilly, Bristol-Myers, and GlaxoSmithKline, among others. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ZYME's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ZYME
Ranked#119 of 479
Ranked#119 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.48 | A | |
| $8.52 | A | |
| $130.88 | A |
Be the first to know about important ZYME news, forecast changes, insider trades & much more!
ZYME News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZYME scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZYME is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZYME is good value based on its book value relative to its share price (2.54x), compared to the US Biotechnology industry average (4.53x)
P/B vs Industry Valuation
ZYME is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ZYME due diligence checks available for Premium users.
Valuation
ZYME price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.62x
Industry
-115.59x
Market
31.65x
ZYME price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.54x
Industry
4.53x
ZYME is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZYME's financial health
Profit margin
Revenue
$31.0M
Net Income
-$23.5M
Profit Margin
-75.8%
ZYME's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ZYME's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$463.1M
Liabilities
$124.3M
Debt to equity
0.37
ZYME's short-term assets ($300.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZYME's short-term assets ($300.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZYME's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ZYME's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.5M
Investing
-$6.2M
Financing
-$8.6M
ZYME's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZYME vs Biotech Stocks
Zymeworks Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.